Table 2. ROI connection details.
RS1 | RS2 | |||||||
Conn | Escit | Plac | T | P | Escit | Plac | T | P |
PCC-RIPC | .98 | 1.30 | −3.7 | .005 | 1.06 | 1.32 | −4.0 | .003 |
PCC-RPHC | .27 | .73 | −4.7 | .001 | .32 | .82 | −7.6 | <.001 |
RIPC-RPHC | .21 | .60 | −3.4 | .008 | .20 | .68 | −8.5 | <.001 |
LIPC-RPHC | .17 | .60 | −4.2 | .002 | .24 | .63 | −4.6 | .001 |
RPHC-ACC | .14 | .40 | −2.5 | .037 | .18 | .48 | −6.0 | <.001 |
RPHC-RMFG | .12 | .43 | −3.6 | .006 | .25 | .43 | −2.2 | 0.058 |
For each significant pairwise connection (Conn) the average connectivity values after Escitalopram (Escit) and Placebo (Plac) administration are shown, together with the paired-sample T-test statistics (degrees of freedom = 9), for both resting states RS1 and RS2. Abbreviations, see main text.